Updates are available Correction dated 2024-03-07
Click to view Correction: https://doi.org/10.1038/s41598-024-53924-1
-
Authors
Mattoli, Luisa https://orcid.org/0000-0002-5566-8919
Proietti, Giacomo
Fodaroni, Giada
Quintiero, Claudio Marzio
Burico, Michela https://orcid.org/0000-0002-6243-9073
Gianni, Mattia https://orcid.org/0009-0004-2955-8240
Giovagnoni, Emiliano
Mercati, Valentino
Santi, Claudio
-
Funding
Funding for this research was provided by:
Aboca S.p.A. Società Agricola
- License Information
-
More Information
Article History
Received: 29 September 2023
Accepted: 13 December 2023
First Online: 2 January 2024
Change Date: 7 March 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-53924-1
Competing interests
: The authors listed below report the following details of affiliation or involvement in an organization or entity with a financial interest in the subject matter or materials discussed in this manuscript. LM, GP, GF, CMQ, GF, MB, GM are employed in Aboca who produce and commercialize the product indicated in the manuscript as B. VM is Honorary President of Aboca SPA. CS is the scientific responsible of a project related to the topic of the present manuscript and committed by Aboca to C.E.M.I.N (UniPG). Product A is a generic drug containing Omeprazole, while “Product B”, Neobianacid, is a Medical device made of substances. Both products are indicated for the treatment reflux diseases and functional dyspepsia.
